Lab10x will accelerate the commercialisation of digital therapeutics and data-driven drug discovery, and is being launched in partnership with Sensyne Health and Evotec.
University of Oxford, its tech transfer office Oxford University Innovation (OUI) and venture fund Oxford Sciences Innovation today unveiled Lab10x, an initiative that will exploit artificial intelligence (AI) to commercialise digital health research.
Clinical AI technology developer Sensyne Health and drug discovery company Evotec fill out Lab10x’s backers. The program is being funded with £5m ($6.5m) for three years initially, though it was unclear who provided the capital.
Lab10x will accelerate drug discovery and development across therapeutic areas,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
